CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Completed · Phase 3
Conditions studied: Uremic Pruritus
In brief
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
Key facts
- Study ID
- NCT03998163
- Run by
- Cara Therapeutics, Inc.
- People needed
- 222
- Starts
- 2019-05-06
- Expected to finish
- 2020-03-06
- Last updated by the study team
- 2021-10-15
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cara Therapeutics Study Site — Escondido, California, United States
- Cara Therapeutics Study Site — Riverside, California, United States
- Cara Therapeutics Study Site — San Diego, California, United States
- Cara Therapeutics Study Site — Victorville, California, United States
- Cara Therapeutics Study Site — Denver, Colorado, United States
- Cara Therapeutics Study Site — Middlebury, Connecticut, United States
- Cara Therapeutics Study Site — Norwich, Connecticut, United States
- Cara Therapeutics Study Site — Coral Gables, Florida, United States
- Cara Therapeutics Study Site — Fort Lauderdale, Florida, United States
- Cara Therapeutics Study Site — Hollywood, Florida, United States
- Cara Therapeutics Study Site — Miami, Florida, United States
- Cara Therapeutics Study Site 2 — Tampa, Florida, United States
- Cara Therapeutics Study Site — Tampa, Florida, United States
- Cara Therapeutics Study Site — Albany, Georgia, United States
- Cara Therapeutics Study Site — Boston, Massachusetts, United States
- Cara Therapeutics Study Site — Roseville, Michigan, United States
- Cara Therapeutics Study Site — Minneapolis, Minnesota, United States
- Cara Therapeutics Study Site — Kansas City, Missouri, United States
- Cara Therapeutics Study Site — Las Vegas, Nevada, United States
- Cara Therapeutics Study Site 2 — Las Vegas, Nevada, United States
- Cara Therapeutics Study Site — Great Neck, New York, United States
- Cara Therapeutics Study Site — Philadelphia, Pennsylvania, United States
- Cara Therapeutics Study Site — Spartanburg, South Carolina, United States
- Cara Therapeutics Study Site — Knoxville, Tennessee, United States
- Cara Therapeutics Study Site — Austin, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.